Therapeutic Targets for Bone and Soft-Tissue Sarcomas.

Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hiroyuki Tsuchiya

Journal: International journal of molecular sciences 2019;20(1):170

PMID: 30621224

Abstract

Due to the rarity and heterogeneity of bone and soft-tissue sarcomas, investigation into molecular targets and new treatments has been particularly challenging. Although intensive chemotherapy and establishment of surgical procedures have improved the outcomes of patients with sarcoma, the curative rate of recurrent and metastatic sarcomas is still not satisfactory. Recent basic science research has revealed some of the mechanisms of progression and metastasis of malignancies including proliferation, apoptosis, angiogenesis, tumor microenvironment, migration, invasion, and regulation of antitumor immune systems. Based on these basic studies, new anticancer drugs, including pazopanib, trabectedin, eribulin, and immune checkpoint inhibitors have been developed and the efficacies and safety of the new drugs have been assessed by clinical trials. This review summarizes new molecular therapeutic targets and advances in the treatment for bone and soft tissue sarcomas.

Address: Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. [email protected].; Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. [email protected].; Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. [email protected].; Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. [email protected].; Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. [email protected].; Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan. [email protected].

DOI: 10.3390/ijms20010170

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/softtissuesarcoma.html

MeSH Terms: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Bone Neoplasms, Drug Therapy, Furans, Humans, Immunotherapy, Adoptive, Indazoles, Ipilimumab, Ketones, Nivolumab, Osteosarcoma, Progression-Free Survival, Pyrimidines, Sarcoma, Soft Tissue Neoplasms, Sorafenib, Sulfonamides, Trabectedin